656 reports of this reaction
1.8% of all KETOPROFEN reports
#12 most reported adverse reaction
HYPERHIDROSIS is the #12 most commonly reported adverse reaction for KETOPROFEN, manufactured by Allegis Pharmaceuticals, Inc.. There are 656 FDA adverse event reports linking KETOPROFEN to HYPERHIDROSIS. This represents approximately 1.8% of all 36,564 adverse event reports for this drug.
Patients taking KETOPROFEN who experience hyperhidrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERHIDROSIS is a less commonly reported adverse event for KETOPROFEN, but still significant enough to appear in the safety profile.
In addition to hyperhidrosis, the following adverse reactions have been reported for KETOPROFEN:
The following drugs have also been linked to hyperhidrosis in FDA adverse event reports:
HYPERHIDROSIS has been reported as an adverse event in 656 FDA reports for KETOPROFEN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERHIDROSIS accounts for approximately 1.8% of all adverse event reports for KETOPROFEN, making it a notable side effect.
If you experience hyperhidrosis while taking KETOPROFEN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.